vafidemstat + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Personality Disorder
Conditions
Borderline Personality Disorder
Trial Timeline
Mar 26, 2021 → Nov 13, 2023
NCT ID
NCT04932291About vafidemstat + Placebo
vafidemstat + Placebo is a phase 2 stage product being developed by Oryzon Genomics for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04932291. Target conditions include Borderline Personality Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04932291 | Phase 2 | Completed |
Competing Products
12 competing products in Borderline Personality Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 77 |
| olanzapine | Eli Lilly | Pre-clinical | 23 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Durvalumab + Tremelimumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| quetiapine extended-release + Placebo | AstraZeneca | Phase 3 | 77 |
| Quetiapine fumarate + Placebo | AstraZeneca | Phase 2 | 52 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 77 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 51 |
| Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin | Bristol Myers Squibb | Phase 1 | 32 |
| PD-1/PD-L1 inhibitors + Chemotherapy | BeOne Medicines | Phase 2 | 49 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 36 |